Kerstin Heinks1, Svenja Boekhoff1, Anika Hoffmann1, Monika Warmuth-Metz2, Maria Eveslage3, Junxiang Peng1,4, Gabriele Calaminus5, Hermann L Müller6. 1. Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, 26133, Oldenburg, Germany. 2. Department of Neuroradiology, University Hospital, 97080, Würzburg, Germany. 3. Institute of of Biostatistics and Clinical Research, University Münster, 48149, Münster, Germany. 4. Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. 5. Department of Pediatric Oncology and Hematology, University Hospital, 53113, Bonn, Germany. 6. Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, 26133, Oldenburg, Germany. mueller.hermann@klinikum-oldenburg.de.
Abstract
CONTEXT: Quality of life (QoL) after childhood-onset craniopharyngioma (CP) is frequently impaired due to tumor and/or treatment-related factors such as endocrine deficits and hypothalamic involvement/lesions. PATIENTS AND METHODS: In a multinational trial, we prospectively analyzed parental and self-assessment of CP patient QoL at 3 months, 1 and 3 years after CP diagnosis related to growth hormone (GH) substitution. 47 of 194 CP recruited between 2007 and 2015 in KRANIOPHARYNGEOM 2007 were analyzed for QoL 1 and 3 years after CP diagnosis. QoL was assessed by Pediatric Quality of Life (PEDQOL) questionnaire and PEDQOL scores of parental and self-assessed QoL during 3 years follow-up after CP diagnosis were analyzed. RESULTS: Parents estimated QoL of their children worse than patients did themselves. GH substitution had no relevant effect on short-term weight and height development. CP patients GH-treated at 3 years follow-up presented at baseline (1 year after diagnosis, before GH substitution) with reduced self-assessed QoL when compared with GH non-treated CP. QoL stabilized during 1-3 years of follow-up in GH-treated patients, whereas non GH-treated patients experienced decreases in autonomy (p = 0.03), cognition (p = 0.01), and physical function (p = 0.04). CONCLUSIONS: Parents assess QoL in CP survivors worse than their children. GH substitution should be considered as a therapeutic option to ameliorate imminent impairments of QoL after CP.
CONTEXT: Quality of life (QoL) after childhood-onset craniopharyngioma (CP) is frequently impaired due to tumor and/or treatment-related factors such as endocrine deficits and hypothalamic involvement/lesions. PATIENTS AND METHODS: In a multinational trial, we prospectively analyzed parental and self-assessment of CP patient QoL at 3 months, 1 and 3 years after CP diagnosis related to growth hormone (GH) substitution. 47 of 194 CP recruited between 2007 and 2015 in KRANIOPHARYNGEOM 2007 were analyzed for QoL 1 and 3 years after CP diagnosis. QoL was assessed by Pediatric Quality of Life (PEDQOL) questionnaire and PEDQOL scores of parental and self-assessed QoL during 3 years follow-up after CP diagnosis were analyzed. RESULTS: Parents estimated QoL of their children worse than patients did themselves. GH substitution had no relevant effect on short-term weight and height development. CP patientsGH-treated at 3 years follow-up presented at baseline (1 year after diagnosis, before GH substitution) with reduced self-assessed QoL when compared with GH non-treated CP. QoL stabilized during 1-3 years of follow-up in GH-treated patients, whereas non GH-treated patients experienced decreases in autonomy (p = 0.03), cognition (p = 0.01), and physical function (p = 0.04). CONCLUSIONS: Parents assess QoL in CP survivors worse than their children. GH substitution should be considered as a therapeutic option to ameliorate imminent impairments of QoL after CP.
Entities:
Keywords:
Craniopharyngioma; Growth hormone; Height; Hypothalamus; Obesity; Quality of life
Authors: Andrea Poretti; Michael A Grotzer; Karin Ribi; Eugen Schönle; Eugen Boltshauser Journal: Dev Med Child Neurol Date: 2004-04 Impact factor: 5.449
Authors: I-Chan Huang; Elizabeth A Shenkman; Walter Leite; Caprice A Knapp; Lindsay A Thompson; Dennis A Revicki Journal: J Clin Epidemiol Date: 2008-10-01 Impact factor: 6.437
Authors: A Bereket; W Kiess; R H Lustig; H L Muller; A P Goldstone; R Weiss; Y Yavuz; Z Hochberg Journal: Obes Rev Date: 2012-05-11 Impact factor: 9.213
Authors: Aylin Mehren; Jale Özyurt; Paula Zu Klampen; Svenja Boekhoff; Christiane M Thiel; Hermann L Müller Journal: J Neurooncol Date: 2018-07-03 Impact factor: 4.130
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Anthony T Yip; Justin D Yu; Minh-Phuong Huynh-Le; Mia Salans; Soumya Unnikrishnan; Alexander S Qian; Ronghui Xu; Ryan Kaner; Iain MacEwan; John R Crawford; Jona A Hattangadi-Gluth Journal: Clin Transl Radiat Oncol Date: 2022-02-25
Authors: Jiska van Schaik; Mila S Welling; Corjan J de Groot; Judith P van Eck; Alicia Juriaans; Marcella Burghard; Sebastianus B J Oude Ophuis; Boudewijn Bakker; Wim J E Tissing; Antoinette Y N Schouten-van Meeteren; Erica L T van den Akker; Hanneke M van Santen Journal: Front Endocrinol (Lausanne) Date: 2022-03-09 Impact factor: 5.555